Dr. Jen Ashton on peptides: hype vs. what studies show

What did @drjenashton actually say?

Dr. Jen Ashton, an ABC News medical contributor and OB-GYN, made a pointed argument: IV peptide therapy is being sold as a wellness fix with claims spanning immune function, skin, muscle, energy, and brain health, but there is "scant to zero published data" on its use in healthy adults. She framed this as a consumer safety issue, not a dismissal of peptides entirely.

Her core challenge was pharmacological: where is the peer-reviewed data on safety, efficacy, dosing, frequency, and side effects for IV peptide use in healthy people? She also flagged the placebo effect, estimated at roughly 30%, as a confounding factor in anecdotal reports. The cocaine and human growth hormone comparisons were rhetorical, meant to illustrate that subjective benefit does not equal safety. She gave herself credit for being open-minded but said she cannot find the evidence she is looking for.

Does the science back this up?

Largely, yes. The published human trial data on peptides like BPC-157, TB-500, CJC-1295, and ipamorelin for wellness indications in healthy adults is thin to nonexistent. Most evidence comes from animal models, and the gap between rodent pharmacology and human clinical outcomes is significant.

BPC-157, perhaps the most discussed peptide in wellness circles, has shown regenerative properties in rat and rodent studies (Sikiric et al., 2018, Current Pharmaceutical Design), but no completed randomized controlled trials in healthy humans have been published for IV wellness use. CJC-1295 and ipamorelin have been studied as growth hormone secretagogues, with some Phase I and II data (Ionescu and Frohman, 2006, Journal of Clinical Endocrinology and Metabolism), but those studies focused on growth hormone-deficient or aging populations, not healthy optimization seekers. GHK-Cu has skin repair data, mostly in vitro and topical (Pickart et al., 2015, Journal of Aging Research). MK-677 has more human data than most, but it is an oral secretagogue, not a peptide in the traditional sense, and its side effect profile includes insulin resistance and edema. Ashton's claim about the evidence gap is defensible.

What did they get wrong (or right)?

Ashton got the core argument right. The evidence base for IV peptide therapy in healthy adults is genuinely sparse, and the wellness industry is running well ahead of the clinical data. That deserves to be said plainly, and she said it.

A few things are worth complicating, though. Her 30% placebo figure is a reasonable ballpark, but placebo rates vary widely by condition, delivery method, and outcome measure. A 2010 Cochrane review (Hrobjartsson and Gotzsche) found placebo effects are strongest for subjective outcomes like pain and nausea, which matters because many peptide benefits claimed are subjective. So the number is not wrong, but it is not a fixed rule either.

Her framing also glosses over the distinction between different peptides. Lumping BPC-157 with MK-677 with GHK-Cu as if they share identical evidence profiles oversimplifies. Some peptides have more human data than others. Saying there are "a couple of exceptions in clinical nutrition and orthopedic surgery" is accurate but vague, and a more precise accounting would strengthen her point rather than dilute it. Her analogy to cocaine, while rhetorically punchy, is a false equivalence. Cocaine has a well-documented abuse and neurotoxicity profile. The concern with most research peptides is not that they are known to be harmful, but that their harms in humans are largely unknown. That is a different category of risk.

What should you actually know?

The honest answer is that peptide therapy sits in a genuinely murky regulatory and scientific space. Most research peptides used in wellness settings are not FDA-approved for those purposes. Many are compounded, which means quality control, purity, and sterility are not standardized across providers. The FDA has flagged BPC-157 and TB-500 as substances of concern in compounded preparations.

That does not mean every person using peptides is being reckless, but it does mean the burden of proof falls on the practitioner prescribing them, not on the skeptic asking for evidence. If a provider cannot point you to human safety data for a specific peptide at a specific dose via a specific route of administration, that is a meaningful gap. Route matters: oral, subcutaneous, and IV delivery have different absorption profiles, different risk surfaces, and in most cases different evidence bases entirely. The IV route carries infection and contamination risks that subcutaneous administration does not. Ashton's "do no harm" framing is clinically appropriate here, even if the rhetorical packaging is a little blunt.

• Ask any provider: what is the specific evidence for this peptide, this dose, this route, in people like me?
• Compounded peptides are not equivalent to pharmaceutical-grade drugs. Purity verification is not guaranteed.
• Animal data does not automatically translate to human benefit or human safety.
• Subjective improvements in energy, mood, or recovery are real experiences but are not clinical evidence of efficacy.